A Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Effect of Steady-State AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Type 2 Diabetes Mellitus

The primary objective of this study is to evaluate the effect of steady-state AZD6793 on the steady-state pharmacokinetics and pharmacodynamics of metformin in participants diagnosed with type 2 diabetes mellitus. This assessment is clinically significant for understanding potential drug-drug interactions between the investigational compound and a standard-of-care antihyperglycemic agent. No secondary objectives were reported.

The sponsor did not provide information regarding the total number of participants. The study population consists of patients diagnosed with Type 2 Diabetes Mellitus. The cohort includes both male and female individuals, including vulnerable populations. The participants fall within age ranges corresponding to codes 3 and 4.

This Phase 3, double-blind, placebo-controlled, multiple-dose, 2-period crossover study is designed to evaluate the effect of steady-state AZD6793 on the steady-state pharmacokinetics and pharmacodynamics of metformin in participants diagnosed with type 2 diabetes mellitus. The research methodology involves a crossover design to assess drug interactions between the investigational product and the standard treatment. Study procedures include a screening visit to confirm eligibility, followed by scheduled visits to monitor physiological responses and drug concentrations. The trial concludes with an end-of-study visit. Participant involvement is subject to the completion of all required study periods, although certain conditions may lead to early termination from the study.

The assessment of efficacy in this Phase 3 clinical trial for Type 2 Diabetes Mellitus involves the evaluation of specified clinical parameters. The methodology for measuring these outcomes is determined by the study protocol to monitor disease progression and therapeutic response.